ストックスクリーナーアプリを入手
46.65
4.07%
-1.98
アフターアワーズ：
46.70
0.05
+0.11%
前日終値:
$48.63
開ける：
$48.27
24時間の取引高:
19.73M
Relative Volume:
1.35
時価総額：
$94.95B
収益：
$48.03B
当期純損益:
$6.05B
株価収益率:
15.75
EPS:
2.9615
ネットキャッシュフロー:
$15.30B
1週間 パフォーマンス:
-0.09%
1か月 パフォーマンス:
+6.51%
6か月 パフォーマンス:
+5.73%
1年 パフォーマンス:
-20.26%
1日の値動き範囲:
$46.12
$48.37
1週間の範囲:
$46.12
$49.99
52週間の値動き範囲:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.65 | 99.00B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Is Bristol Myers Squibb Company stock a safe investment in uncertain markets2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
Good Life Advisors LLC Decreases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company (BRM) stock a contrarian opportunityMarket Trend Review & Safe Capital Preservation Plans - newser.com
Boston Partners Sells 3,760,655 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target - Finviz
Is Bristol Myers Squibb Company Celegne Contingent stock resilient in recession scenarios2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Police & Firemen s Retirement System of New Jersey Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Purchases 15,599 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Arvest Bank Trust Division - MarketBeat
Allianz SE Lowers Position in Bristol Myers Squibb Company $BMY - MarketBeat
Blood thinner failure thins BMS shares - The Pharma Letter
Bristol Myers, J&J halt heart drug trial after interim review - ETPharma.com
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? - Benzinga
Scotiabank Initiates Coverage on Bristol Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers, J&J’s new blood thinner fails first big test - BioPharma Dive
Bristol Myers, J&J stop blood clotting drug trial after interim review - Reuters
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy - Benzinga
Wealth Alliance LLC Cuts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Vestmark Advisory Solutions Inc. Trims Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb shares slide after halting key heart trial - MSN
Bristol-Myers Squibb stock falls after discontinuing acute coronary trial By Investing.com - Investing.com Canada
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com
Bristol Myers (BMY) Drops Following Phase 3 Trial Halt - GuruFocus
Bristol Myers falls after halting heart drug trial - TradingView
Bristol Myers Squibb discontinues Librexia ACS trial after review By Investing.com - Investing.com Canada
Bristol Myers Squibb Company $BMY Shares Sold by Nwam LLC - MarketBeat
Cherokee Insurance Co Takes $1.42 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Update on phase 3 Librexia ACS trial - MarketScreener
Candriam S.C.A. Sells 92,461 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Forsta AP Fonden Has $19.34 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Q&A: BioNTech co-founders discuss bispecific efforts, Bristol Myers deal, and the irony of competing with Pfizer - Endpoints News
Wealth Quarterback LLC Raises Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by KBC Group NV - MarketBeat
ProShare Advisors LLC Acquires 37,125 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb’s Oncology Strategy Gains Momentum - AD HOC NEWS
SCRI, BMS Expand Collaboration to Accelerate Patient Enrollment - Contract Pharma
Bristol Myers Squibb, Sarah Cannon expand oncology trial partnership - Investing.com
Does Bristol-Myers Squibb’s Rebound Signal Opportunity After Recent Biotech Acquisitions? - Yahoo Finance
Bristol Myers (NYSE: BMY) and SCRI broaden cancer trial access via Accelero at 200+ sites - Stock Titan
Zions Bancorporation National Association UT Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Evotec and BMS partnership yields IND approval - BioWorld MedTech
Evotec Receives $5 Million Milestone Payment From Bristol Myers Under Protein Degradation Partnership - MarketScreener
Bristol Myers Squibb Company $BMY Stake Boosted by denkapparat Operations GmbH - MarketBeat
Privacy notice center - Bristol Myers Squibb
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - ACCESS Newswire
Published on: 2025-11-12 00:59:26 - newser.com
Evotec gets USD 5 mln milestone payment from Bristol Myers Squibb - MarketScreener
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership - TradingView
Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating - Insider Monkey
Jim Cramer on Bristol-Myers: “I’m Backing off on It” - Insider Monkey
Bristol Myers Squibb Co. Stock Rises Monday, Still Underperforms Market - 富途牛牛
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
0.38%
0.22%
大文字化:
|
ボリューム (24 時間):